The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 plus bevacizumab (IRIS+BV) and modified FOLFIRI plus BV (mFOLFIRI+BV) in patients (pts) with metastatic colorectal cancer (mCRC): The result of efficacy report of T-CORE0702.
H. Andoh
No relevant relationships to disclose
S. Kato
No relevant relationships to disclose
M. Gamoh
No relevant relationships to disclose
T. Yamaguchi
No relevant relationships to disclose
M. Sakayori
No relevant relationships to disclose
Y. Sasaki
No relevant relationships to disclose
T. Mori
No relevant relationships to disclose
H. Ohori
No relevant relationships to disclose
T. Yoshioka
No relevant relationships to disclose
C. Ishioka
Research Funding - Chugai Pharma; Taiho Pharmaceutical